Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...

The AAP published its own vaccine schedule in a break from federal guidance. HHS secretary RFK Jr. took to social media to ...

In people with HIV infection, new-onset diabetes is independently predicted by higher leukocyte counts — mostly within the ...

Merck KGaA agreed to collaborate with Skyhawk Therapeutics Inc. to develop neurological therapies in a deal that could be ...

Shares have plunged by a third in the past year. Investors are worried about expiring patents for Keytruda, the cancer ...

After six days of gains, shares dropped, reflecting mixed momentum. See insights on earnings, cost-cutting, and analyst ...

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Merck KGaA agreed to a deal with RNA biotech Skyhawk Therapeutics that could top out at $2 billion. Roche’s Genentech terminated a cell therapy partnership with Adaptive Biotechnologies, ending what ...

Recent advancements in Merck's (MRK) product portfolio, including the FDA's Breakthrough Therapy Designation for ifinatamab deruxtecan and several approvals of their flagship drug KEYTRUDA, are ...

Stamford: SpringWorks Therapeutics, Inc., a healthcare company of Merck, has received marketing authorization from the ...

Fidelity Enhanced Large Cap Core is a growth-focused fund with tech exposure, balanced strategy, and strong risk-adjusted ...

Per management, Keytruda will remain a key revenue driver for the company in the second half of 2025, along with the Animal ...